SCHEMBL14596199

SCHEMBL14596199

CN(C)CCCNc1nc(CN(C)C(=O)NCc2cccc(F)c2)nc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.55
APP P05067 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPK1 P28482 1/20 0.47
RAD52 P43351 4/20 0.46
KMT2A Q03164 2/20 0.46
CCNE2 O96020 1/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46
POLB P06746 3/20 0.44
TOP2A P11388 1/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
NPC1 O15118 1/20 0.43
SLC2A1 P11166 1/20 0.43
APOBEC3A P31941 1/20 0.43
RAB9A P51151 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14596187 0.91 ALDH1A1 (0.54) FLT3ALDH1A1MAPK1RAD52KMT2A
SCHEMBL14596224 0.86 POLB (0.48) FLT3ALDH1A1MAPK1RAD52KMT2A
SCHEMBL14596196 0.85 ACHE (0.53) FLT3APPALDH1A1MAPK1RAD52
SCHEMBL13159049 0.84 FLT3 (0.62) FLT3APPALDH1A1MAPK1RAD52
SCHEMBL14596205 0.84 FLT3 (0.50) FLT3ALDH1A1MAPK1RAD52KMT2A
SCHEMBL14596185 0.83 ALDH1A1 (0.52) FLT3ALDH1A1MAPK1RAD52KMT2A
SCHEMBL14596207 0.83 RAD52 (0.59) FLT3APPALDH1A1MAPK1RAD52
SCHEMBL14596209 0.83 POLB (0.49) FLT3ALDH1A1MAPK1RAD52KMT2A
SCHEMBL14596189 0.83 FLT3 (0.56) FLT3ALDH1A1MAPK1RAD52KMT2A
SCHEMBL14585534 0.82 FLT3 (0.49) FLT3APPALDH1A1MAPK1RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment TP53, TP53BP1, ACIN1 FLT3 191/4885APP 4431/4885ALDH1A1 1994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.